Glycated serum stimulation of macrophages in GK- and streptozotocin-rats for the proliferation of primary cultured smooth muscle cells of the aorta

Immunopharmacology

Volumn 40, Issue 2, 1998, Pages 105-118

  Kimura, Ikuko ^a   Nagamori, Akemi ^a   Honda, Ritsu ^a   Kobayashi, Shinjiro ^b  

^a Fac Pharmaceutical Sci   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cholesterol; Conditioned medium; Endothelial cells; Glycated serum; Macrophages; NIDDM model (GK rat, STZ diabetic rat); Platelet derived growth factor BB; Proliferation of vascular smooth muscle cells

Indexed keywords

CHOLESTEROL; GLUCOSE; GLYCOSYLATED PROTEIN; PLATELET DERIVED GROWTH FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTERY MUSCLE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER;

ANIMALS; ANTIBODIES; AORTA; CELL DIVISION; CELLS, CULTURED; CHOLESTEROL; CULTURE MEDIA, CONDITIONED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GLUCOSE; GLYCOSYLATION; LIPOPROTEINS, LDL; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MALE; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, INBRED STRAINS; RATS, WISTAR;

EID: 0031725333     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(98)00024-1     Document Type: Article

References (55)

1. Brownlee M., Vlassara H., Cerami A. Nonenzymatic glycosylation and pathogenesis of diabetic complications. Ann. Internal Med. 101:1984;527-537.
2. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care. 15:1992;1835-1843.
3. Bucala R., Tracey K.J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J. Clin. Invest. 87:1991;432-438.
4. Chamley J.H., Campbell G.R., McConnell J.D., Gröschel-Stewart U. Comparison of vascular smooth muscle cells from adult human, monkey and rabbit in primary culture and subculture. Cell Tissue Res. 177:1977;503-522.
5. Chamley-Campbell J., Campbell G.R., Ross R. The smooth muscle cells in culture. Physiol. Rev. 59:1979;1-61.
6. Chappey O., Dosquet C., Wautier M.-P., Wautier J.-L. Advanced glycation end products, oxidant stress and vascular lesions. Eur. J. Clin. Invest. 27:1997;97-108.
7. Charonis A.S., Tsilibary E.C. Structural and functional changes of laminin and type IV collagen after nonenzymatic glycation. Diabetes. 41:1992;49-51. (Suppl. 2).
8. DiCorleto P.E. Cultured endothelial cells produce multiple growth factors for connective tissue cells. Exp. Cell Res. 153:1984;167-172.
9. Esposito C., Gerlach H., Brett J., Stern D., Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J. Exp. Med. 170:1989;1380-1407.
10. Folkman J., Haudenschild C. Angiogenesis in vitro. Nature. 288:1980;551-556.
11. Ginsberg H.N. Lipoprotein physiology in nondiabetic and diabetic state. Relationship to atherogenesis. Diabetes Care. 14:1991;839-855.
12. Goto Y., Kakizaki M., Masaki N. Spontaneous diabetes produced by selective breeding of normal Wistar rats. Proc. Jpn. Acad. 51:1975;80-85.
13. Greene D.A., Lattimer S.A., Sima A.A.F. Sorbitol phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complication. New Engl. J. Med. 316:1987;599-606.
14. Ho, R.S., Aranda, C.G., Tillery, S.J., Botelho, L.H., Oliveri, M., Meserve, C., Mcintoslo, Ro., Kerestan, S., Foley, J.E., 1988. In-vivo and in-vitro glucose metabolism in a low-dose streptozotocin rat model of non insulin-dependent diabetes. In: Shafrir, E., Renold, A.E. (Eds.), Frontiers in Diabetes Research - Lessons from Animal Diabetes. John Libbey, London and Paris, pp. 288-294.
15. Ikeda, H., Odaka, H., Matsuo, T., Suzuki, K., Toyoda, T., Goto, Y., 1991. Diabetogenicity of sucrose in GK rats. In: Goto, Y., Kanazawa, Y. (Eds.), Lessons from animal diabetes. Smith-Gordon, London, pp. 17-22.
16. Kimura I., Nagaura T., Naitoh T., Kobayashi S., Kimura M. Heparin inhibits the progression phase of subcultured endothelial cell proliferation in rat aorta. Jpn. J. Pharmacol. 60:1992;369-375.
17. Kimura I., Naitoh T., Okabe M., Kimura M. Platelet-derived growth factor (PDGF) accelerates induction of competence, and heparin does not inhibit PDGF-induced competence in primary cultured smooth muscle cells of rat aorta. Jpn. J. Pharmacol. 59:1992;51-56.
18. 2α-responses is inhibited by lipoxygenase- but not cyclooxygenase-inhibitors in mesenteric veins and arteries of mouse and rat. Jpn. J. Pharmacol. 64:1994;65-70.
19. Kimura I., Nakano Y., Naitoh T., Okabe M., Kimura M. Diabetic GK rat plasma but not normal Wistar rat plasma induces insulin-stimulated DNA synthesis in primary cultured smooth muscle cells in GK rat aorta. Jpn. J. Pharmacol. 64:1994;195-200.
20. Kimura M., Kimura I., Okabe M., Beppu T. Dual modes of action of platelet-derived growth factor and its inhibition by trichostatin-A for DNA synthesis in primary cultured smooth muscle cells of rat aorta. Biol. Pharm. Bull. 17:1994;399-402.
21. King G.L., Shiba T., Oliver J., Inoguchi T., Brursell S.-E. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu. Rev. Med. 45:1994;179-188.
22. Kirstein M., Aston C., Vlassara H. Insulin like growth factor 1 (IGF-1) mRNA expression induced in human monocytes by advanced glycosylation end products (AGE): role in diabetes and aging (Abstract). Diabetes. 39:1990;182A. (Suppl. 1).
23. Kirstein M., Grett J., Radoff S., Ogawa S., Stem D., Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc. Natl. Acad. Sci. U.S.A. 87:1990;9010-9014.
24. Kobayashi S., Mimura Y., Naitoh T., Kimura I., Kimura M. Chemical structure-activity of cnidium rhizome-derived phthalides for the competence inhibition of proliferation in primary cultures of mouse aorta smooth muscle cells. Jpn. J. Pharmacol. 63:1993;353-359.
25. Kobayashi S., Nagaura T., Kimura I., Kimura M. Interferon-γ-activated macrophages enhance angiogenesis from endothelial cells of rat aorta. Immunopharmacology. 27:1994;23-30.
26. Kobayashi S., Okabe M., Kimura I., Kimura M. Interferon-γ-activated macrophages release interleukin-1α for tube formation from endothelial cells in rat aorta. Immunopharmacology. 31:1995;93-101.
27. Kobayashi S., Kimura I., Kimura M. Diabetic state-modified macrophages in GK rat release platelet-derived growth factor-BB for tube formation of endothelial cells in rat aorta. Immunopharmacology. 35:1996;171-180.
28. Kobayashi S., Luo B., Okabe M., Kimura I., Kimura M. The diabetic state increases the activity but not the number of peritoneal macrophages in the GK rat promoting tube formation of cultured endothelial cells in rat aorta. Biol. Pharm. Bull. 19:1996;199-202.
29. Krantz S., Brandt R., Gromoll B. Binding sites for short-term glycated albumin on peritoneal cells of the rat. Biochim. Biophys. Acta. 1177:1993;15-24.
30. Kwok C.F., Goldstein B.J., Muller-Wieland D., Lee T.-S., Kahn C.R., King G.L. Identification of persistent defects in insulin receptor structure and function in capillary endothelial cells from diabetic rats. J. Clin. Invest. 83:1989;127-136.
31. Libby P., Warner S.J.C., Friedman G.B. Interleukin-1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J. Clin. Invest. 81:1988;487-498.
32. Lubec G., Pollak A. Reduced susceptibility of nonenzymatically glycosylated glomerular basement membrane to proteases: is thickening diabetic glomerular basement due to reduced proteolytic degradation? Renal Physiol. 3:1980;4-8.
33. Makita Z., Vlassara H., Cerami A., Bucala R. Immuno chemical detection of advanced glycosylation end products in vivo. J. Biol. Chem. 267:1992;5133-5138.
34. Malden L.T., Chait A., Raines E.W., Ross R. The influence of oxidatively modified low density lipoproteins on expression of platelet-derived growth factor by human monocyte-derived macrophages. J. Biol. Chem. 266:1991;13901-13907.
35. Merimee T.J. Diabetic retinopathy: a synthesis of perspectives. New Engl. J. Med. 322:1990;978-983.
36. Mimura Y., Kobayashi S., Okabe M., Kimura I., Kimura M. Anti-competence effects of synthetic phthalide derivatives on platelet-derived growth factor-induced DNA synthesis in primary cultures of rat aorta smooth muscle cells. Biol. Pharm. Bull. 18:1995;1660-1664.
37. Parums, D.V., 1992. Macrophages in cardiovascular disease. In: Lewis, C.E., McGee, J.O'D. (Eds.), The Natural Immune System. The Macrophage. IRL Press, Oxford, pp. 361-390.
38. Patterson M.K. Jr. Measurement of growth and viability of cells in culture. Methods Enzymol. 58:1979;141-152.
39. Pongor S., Ulrich P.C., Bencsath F.A., Cerami A. Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc. Natl. Acad. Sci. U.S.A. 81:1984;2684-2688.
40. Portha B., Serradas P., Bailbe D., Suzuki K., Goto Y., Giroix M.-H. β-Cell insensitivity to glucose in the GK rat, a spontaneous nonobese model for type II diabetes. Diabetes. 40:1991;486-491.
41. Radoff S., Vlassara H., Cerami A. Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified nonenzymatically by advanced glycosylation end products. Arch. Biochem. Biophys. 263:1988;418-423.
42. Raines E.W., Dower S.K., Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science. 243:1989;193-196.
43. Ross R. The pathogenesis of atherosclerosis - an update. New Engl. J. Med. 314:1986;488-500.
44. Ross R., Agius L. The process of atherogenesis - cellular and molecular interaction: from experimental animal models to humans. Diabetologia. 35:1992;S34-S40. [Suppl. 2].
45. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
46. Schmidt A.M., Hori O., Brett J., Yan S.D., Wautier J.-L., Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler. Thromb. 14:1994;1521-1528.
47. Schwartz, S.M., 1978. Selection and characterization of bovine aortic endothelial cells. In Vitro 14, 966-980.
48. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. New Engl. J. Med. 320:1989;915-924.
49. Tezuka M., Koyama N., Morisaki N., Saito Y., Yoshida S., Araki N., Horiuchi S. Angiogenic effects of advanced glycation end products of maillard reaction on cultured human umbilical cord vein endothelial cells. Biochem. Biophys. Res. Commun. 193:1993;674-680.
50. Vlassara H., Brownlee M., Cerami A. High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc. Natl. Acad. Sci. U.S.A. 82:1985;5588-5592.
51. Vlassara H., Brownlee M., Manogue K.R., Dinarello C., Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science. 240:1988;1546-1548.
52. Vlassara H. Receptor-mediated interactions of advanced glycosylation end products with cellular components within diabetic tissues. Diabetes. 41:1992;52-56. (Suppl. 2).
53. Vlassara H. Recent progress on the biologic and clinical significance of advanced glycation end products. J. Lab. Clin. Med. 124:1994;19-30.
54. Wilcox J.N., Smith K.M., Williams L.T., Schwartz S.M., Gordon D. Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J. Clin. Invest. 82:1988;1134-1143.
55. Yagihashi S., Goto Y., Kakizaki M., Kaseda N. Thickening of glomerular basement membrane in spontaneously diabetic rats. Diabetologia. 15:1978;309-312.